Skip to content
StockMarketAgent
Direct answer
HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $497, high $798, with mid-point at $647.
Stock analysis

HCA HCA fair value $497–$798

HCA
By StockMarketAgent.AI team· supervised by
Analisado: 2026-05-13Próxima atualização: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Preço
$426.37
▲ +220.89 (+51.81%)
Valor justo
$647
$497–$798
Classificação
Compra forte
confidence 88/100
Potencial de alta
+51.8%
upside to fair value
Margem de segurança
$550.17
MoS level · 15%
Capitalização de mercado
$94.6B
P/E fwd 12.9
Fonte em inglêsPT
Exibindo a fonte em inglês enquanto traduzimos
Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.

§1 Resumo executivo

  • Composite fair value $647 with high case $798.
  • Implied upside of 51.8% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$647
Margin of safety
+34.1%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$426.37Price
Low $496.77
Mid $647.26
High $798.49

HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Local market density and scale
    Local market density and scale advantages driving industry-leading margins.
  • Demographic tailwinds with an aging
    Demographic tailwinds with an aging population ensuring consistent volume.
  • Bull thesis
    Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.

§2 Cenário pessimista

A prolonged period of elevated interest rates combined with flat commercial volumes and margin compression to 13% would severely stress HCA's free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics., threatening the heavily leveraged capital structure and ending the share repurchase algorithm.

Como esta tese pode falhar

Severe Reimbursement Cuts

· Medium

Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.

FV impact
Downside anchoring near Expected Value of $421
Trigger
12 to 24 months

Structural Labor Shortage

· High

Persistent clinical staff shortages force a permanent reliance on expensive contract labor, eroding operating margins below 14%.

FV impact
Valuation anchors to Forward Earnings mid $420
Trigger
6 to 18 months

Debt Cost Spiral

· Low

Refinancing the massive $48.7B net debt load at significantly higher rates extinguishes the aggressive buyback program.

FV impact
Severe reduction in Owner Earnings fair value and DCF upside
Trigger
24 to 36 months
Sinais de alerta antecipado para monitorar
MétricaAtualLimite de gatilho
Operating margin falling below 14.0% in consecutive quarters.MonitorDeterioration versus the report thesis
Year-over-year reduction in diluted shares outstanding falling below 3%.MonitorDeterioration versus the report thesis
Sustained acceleration in contract labor costs.MonitorDeterioration versus the report thesis
Negative shift in payer mix toward government and uninsured.MonitorDeterioration versus the report thesis
Deterioration of free cash flow conversion below $7B annually.MonitorDeterioration versus the report thesis

§3 Histórico financeiro

Demonstração de resultados — últimos seis períodos
ItemT−0T−1T−2T−3T−4CAGR
Período2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Receita—$60.23B$64.97B$70.60B$75.60B+5.8%
Lucro bruto—$23.18B$25.58B$28.68B$31.37B+7.9%
Lucro operacional—$9.05B$9.63B$10.55B$11.97B+7.2%
Lucro líquido—$5.64B$5.24B$5.76B$6.78B+4.7%
LPA (diluído)—$19.15$18.97$22.00$28.33+10.3%
EBITDA—$13.29B$12.72B$13.90B$15.60B+4.1%
P&D——————
SG&A$26.78B$27.69B$29.49B$31.17B—+3.9%

Pontuações de qualidade

OCF / Lucro líquido
1.86×
>1 indica alta qualidade dos lucros
Limite de qualidade contábil
Fail
Limite ajustado ao setor
ROIC
22.4%
Retorno sobre o capital investido
Seção 3

Numbers analysis

Fluxo de caixa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alocação de capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Assinantes individuais — a partir do §411 seções a mais

Leia a análise completa — 11 seções a mais.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Relatório completo para cada ticker coberto
24 meses de arquivo de classificações
Briefings da lista de acompanhamento + alertas de mudança de classificação
Exportação PDF + DOCX em qualquer idioma
Iniciar teste grátis
Cancele a qualquer momento.
FAQ

HCA — frequently asked questions

  1. Based on our latest analysis, HCA looks meaningfully undervalued. The current price is $426 versus a composite fair-value midpoint of $647 (range $497–$798), which implies roughly 51.8% upside to the midpoint.

Related coverage

Names readers of HCA also follow

Same archetype: mature-compounder